Deleterious effects of nervous system in the offspring following maternal SARS-CoV-2 infection during the COVID-19 pandemic

Ruting Wang1,4, Zifeng Wu2,4, Chaoli Huang2, Kenji Hashimoto3, Ling Yang1✉ and Chun Yang2✉

© The Author(s) 2022

INTRODUCTION
Coronavirus disease 2019 (COVID-19) is a highly infectious disease caused by the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) declared COVID-19 as a global pandemic in March 2020. It has since been called “the most critical global health disaster of the century and the greatest challenge facing humanity since World War II” [1, 2]. COVID-19 has spread rapidly across the globe, posing enormous health, economic and social challenges to humanity. As a respiratory infectious disease, SARS-CoV-2 is transmitted mainly through droplets, respiratory secretions, and direct contact [3]. However, recent studies have shown that SARS-CoV-2 can affect the health of the next generation through vertical transmission from mother to child [4, 5]. Although COVID-19 is considered as a respiratory disease with the main clinical manifestations of fever, cough, and malaise, SARS-CoV-2 still causes damage to other organs, including the central nervous system (CNS) with symptoms such as dizziness, headache, and impaired consciousness [6]. Current human autopsy studies have determined that patients who died from COVID-19 had detectable viral RNA transcription products in brain tissue, viral proteins in endothelial cells of the olfactory bulb, and genetic sequencing of the cerebrospinal fluid showed the presence of SARS-CoV-2, suggesting that SARS-CoV-2 has the ability to invade the nervous system [7-9]. During the COVID-19 pandemic, the number of pregnant women infected with SARS-CoV-2 worldwide has been steadily increasing, and we have to consider whether maternal infection may have adverse effects on their offspring. The fetal nervous system is in a state of development from the third week of gestation and this process continues until adulthood [10].

MECHANISMS
Maternal immune activation (MIA)
Since the COVID-19 epidemic, several studies have reported that the clinical symptoms and laboratory findings of patients with combined SARS-CoV-2 infection in pregnancy are consistent with those of the general population, with patients showing increased C-reactive protein (CRP) and decreased lymphocytes in their hemogram [12]. Tanacan et al. found that pregnant women with COVID-19 had significantly increased pregnancy complications and inflammatory markers [13]. In addition, the inflammatory cytokines interferon (IFN)-γ and interleukin (IL)-6 were significantly increased, while IL-10 and IL-17 were decreased [13]. Since the fetus is a semi-allograft to the maternal body, pregnancy is also a specific immune adaptation process [14]. On the one hand, increased production of inflammatory cytokines such as IL-4 and IL-10 provides a suitable microenvironment of immunologic tolerance. On the other hand, altered expression of inflammatory cytokines such as IL-1 and tumor necrosis factor (TNF)-α is associated with increased pregnancy complications, such as miscarriage, and preterm delivery [15, 16]. Thus, homeostasis of inflammatory cytokines is essential to a healthy pregnancy, while elevated levels of inflammatory cytokines suggest a state of MIA.
Fetal nervous system injury. Maternal trophoblasts, specific natural killer cells, and meconium leukocytes secrete IFN-γ during the pregnancy and are involved in the differentiation of meconium natural killer cells, placenta formation, and meconium maintenance [17]. However, congenital infection causes miscarriage and reduced IFN-γ levels. IFN-γ levels have been reported to be lower in patients with severe COVID-19 infection than in healthy pregnant women and in patients with mild to moderate infection [18]. Similarly, a significant increase in IL-6 levels is observed in patients with severe COVID-19 [19]. Excessive production of IL-6 is associated with adverse pregnancy outcomes, such as preterm birth, premature rupture of membranes, and chorioamnionitis [20]. On the contrary, IL-10 is involved in the immune tolerance process during the pregnancy due to its anti-inflammatory effects and is mainly produced by placental chorionic trophoblasts, uterine natural killer cells, and metaphase mononuclear cells [21]. The decreased IL-10 levels in pregnant women with COVID-19 may be a factor in the impaired immune tolerance in this population and is associated with miscarriage [22]. Adverse pregnancy outcomes such as preterm birth, premature rupture of membranes, and chorioamnionitis can cause neonatal brain damage and even lifelong nervous system disorders [23]. In addition, increased secretion of inflammatory cytokines such as IL-8, IL-1β, and CRP, were found to be associated with microcephaly, ventricular enlargement, and low intelligence quotient [24], suggesting that inflammatory cytokines can cross the placenta and blood-brain barrier (BBB) and directly affect fetal neurodevelopment.

Vulnerability to psychiatric disorders in offspring. There is a study that reported that pregnant women during the influenza pandemics had a high incidence of psychiatric disorders in their offspring, including schizophrenia, autism spectrum disorder (ASD), and attention-deficit hyperactivity disorder (ADHD) [25]. Similar results have been obtained in animal experiments, where an animal model of maternal immune activation was constructed by administering polyinosinic-polycytidylic acid (Poly I:C) to pregnant mice, and it was found that exposure of mice on days 10–12 of embryonic life resulted in damage to the developing basal ganglia and offspring with defects in prepulse inhibition and latent inhibition that are similar to those found in ASD and schizophrenia individuals [26]. A study of Chinese mothers during the COVID-19 epidemic showed that most mothers were infected with SARS-CoV-2 around the third trimester, and their offspring had reduced motor, communication, and social performance compared to normal levels at 3 months of age [27]. The occurrence of infection in mothers during the first trimester may be a risk factor for ASD and schizophrenia in their offspring [28]. Given that IL-6 has the potential to alter cognitive behavior in offspring [29] and that elevated levels of IL-8, TNF-α, and CRP are associated with an increased risk of schizophrenia in offspring [30, 31], the effects of immune activation responses induced by maternal SARS-CoV-2 infection on fetal brain development may make the offspring more susceptible to neuropsychiatric disorders.

Direct effects of SARS-CoV-2
Past epidemiological studies have shown that a large number of viral infections during maternal pregnancy can lead to abnormalities in the nervous system in the fetus [32]. Although studies show that the probability of mother-to-child transmission of COVID-19 is extremely low, the possibility of vertical transmission has been reported in several cases [5, 33]. In a study from Wuhan, China, a primigravida was diagnosed with SARS-CoV-2 infection at 34 weeks of gestation and delivered a baby by cesarean section in a negative pressure isolation room at 38 weeks of gestation, during which she wore an N95 mask without contact with the newborn [4]. However, the levels of IgM and IgG antibodies were significantly elevated 2 h after birth, suggesting the possibility of intraterine infection. It is known that IgM antibodies cannot pass through the placenta, while IgG antibodies can be transmitted through the placenta, and IgM antibodies usually appear 3–7 days after infection, suggesting that SARS-CoV-2 may cause indirect infection of the fetus through vertical transmission from mother to child.

During fetal brain development, genetic defects, environmental disturbances or pathogens can lead to defective mitosis or apoptosis of neural stem cells, which can disrupt the stem cell homeostasis and affect the differentiation of stem cells to other neural cells, manifesting as neurodevelopmental disorders, such as microcephaly and multiple sclerosis [34]. And the formation of neural circuits and changes in their function can lead to other mental disorders, such as ASD and schizophrenia [31]. It was found that SARS-CoV-2 may invade the CNS through blood circulation and peripheral nerve via the olfactory nerve [35].

The immune system plays an important role in nervous system injury caused by viral infection [36]. Persistent infection with SARS-CoV-2 and its infection of macrophages, microglia, and astrocytes in the CNS activates the inflammatory response of the body, causing immune system damage and brain injury [37]. At the same time, immune system damage and peripheral lymphocytopenia caused by SARS-CoV-2 increase the risk of secondary bacterial infections and exacerbate neurological damage [38]. A large number of deaths caused by COVID-19, most of which are due to multiple organ failures caused by viral-induced systemic inflammatory response syndrome (SIRS) or SIRS-like immune disorders [39].

Angiotensin-converting enzyme 2 (ACE2), a cardiovascular and cerebrovascular protective factor, is also abundantly expressed in glial cells, and SARS-CoV-2 has a high affinity for ACE2, and its spike protein interacts with ACE2 to disrupt the BBB and attack the nervous system. Children complete myelin development by 3 months of age [41]. It is suggested that pregnant women, as a more vulnerable group, are more emotionally vulnerable during their pregnancy and suffer from higher levels of psychological stress. In turn, excessive maternal stress during pregnancy produces prenatal stress damage that increases the risk of fetal neurodevelopmental disorders [45]. Animal studies have shown that prenatal stress leads to shorter and less complex dendrites, reduced myelin, and altered synapses [46]. To determine whether changes in brain function occur in the offspring of women with high maternal stress, Thomason et al. performed functional magnetic resonance imaging on 118 fetuses at a mean gestational age of 32.9 weeks and found that increased maternal prenatal stress and negative emotions were associated with alterations in fetal frontoparietal, striatal, and temporoparietal neural connectivity (β = 0.82, P < 0.001), suggesting that high maternal stress and negative emotions during the pregnancy can have an unwanted impact on the nervous system of the offspring [47].

Deoni et al. found that children born after the COVID-19 pandemic were found to have lower developmental scores and these children had significantly lower language, motor, and overall cognitive skills [48]. Anti-epidemic measures may block parent-child emotional interactions and negatively affect children's brains and behavior [49]. What's more, this may be related to maternal...
stress and negative emotions during pregnancy affecting the structure and connectivity of the developing brain of the fetus, leading to potential delays in its motor, cognitive, and behavioral development [50]. The fetal brain is born with a strong capacity to learn and adapt, but is also very fragile and vulnerable to environmental exposures [51]. Maternal-fetal interaction and “kangaroo” care facilitate neurodevelopmental processes, including myelin formation and synaptogenesis [52]. On the other hand, exposure of the fetus to stress-related hormones such as cortisol might affect the structural and functional changes of the brain [53]. This is likely that higher cortisol levels in the mother during the pregnancy lead to lower cortisol levels in the infant at birth, which can dysregulate the hypothalamic-pituitary-adrenal axis and affect neurological development in the newborn [54] (Fig. 1).

PROPHYLACTIC AND TREATMENT STRATEGIES

There is still no specific medicine for COVID-19, and the most common treatments for infection in pregnant women are antibiotics, antivirals, and oxygen support. However, both the public and the scientific community pay great attention to the safety and impacts of these treatment measures on the fetus. A meta-study analysis showed that the use of antibiotics and antivirals is higher in Asian countries than in other countries, suggesting a possibility of antibiotic abuse [55]. The use of immunosuppressive drugs is associated with the occurrence of adverse outcomes and potentially serious complications, and their use should be minimized, and improved therapeutic approaches through risk stratification are recommended. Therefore, effective prophylactic is important for disease management in pregnant women. Given that current studies have not reported serious adverse reactions in pregnant women after receiving the COVID-19 vaccine [56], a vaccine with nutritional support seems to be an effective approach. For pregnant women who have already developed psychological problems, appropriate use of drug medication and psychological treatment are recommended and prescribed under the guidance of physicians (Fig. 2).

Vaccination

Vaccination against infectious pathogens is one of the most influential public health interventions to reduce infection-related morbidity and mortality worldwide [57]. Theoretically, anti-SARS-CoV-2 immunoglobulins (IgG and IgA) are transmitted to the newborn through the placenta and breast milk after vaccination of pregnant women, providing humoral immunity. Regarding the safety of the vaccine in pregnant women, several studies have shown that no serious adverse events occurred in pregnant and lactating women who received the Pfizer/BioNTech vaccine, and no vaccine-associated mRNA was detected in breast milk collected 4 to 48 hours after vaccination, indicating that the vaccine is safe, although more studies are needed to analyze its effectiveness and impact on the offspring in the future [58–60]. Societies such as the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) continue to advocate for the availability of COVID-19 vaccine to pregnant and breastfeeding women [61]. WHO revised its statement on January 29, 2021, to allow vaccination of pregnant women at high risk of SARS-CoV-2 exposure (e.g., health workers) or with comorbidities that increase their risk of serious illness after consultation with their health care providers [56].

Nutrition

Based on previous experience with disease pandemics and experience with other respiratory viruses and animal models,
increasing maternal choline levels and other nutrient levels may reduce the effects of infection on fetal brain development [25]. Choline supplementation may reduce the increase in fetal IL-6 levels caused by RNA virus stimulation and may decrease anxiety [62]. Maternal choline levels are associated with the development of attention and orienting regulation in early childhood [63]. Maternal choline levels are associated with the development of anxiety and other neurodevelopmental outcomes [64, 65]. Therefore, it is recommended that pregnant women consume vitamin D with folic acid according to a standard prenatal vitamin formula and moderate choline supplementation from beef, egg yolk, and soy.

Antidepressants

The use of antidepressants such as selective serotonin reuptake inhibitor (SSRI) may be associated with a reduced risk of clinical deterioration in patients with SARS-CoV-2 infection. It may benefit depression patients with COVID-19 infection, since SSRIs exert anti-inflammatory effects on the damaged striatal neurons [28, 66]. Although using antidepressants during the pregnancy may increase the risk of ASD in offspring [67], a subsequent systematic review did not show an absolute contraindication to antidepressants and there was insufficient evidence of an association between antidepressants and adverse events [68]. Therefore, considering the safety of medication use in pregnant women, clinicians should balance the risks and benefits to develop an optimal treatment strategy on the basis of the actual situation.

Psychological intervention

Psychotherapy is a safer strategy with less adverse effects than pharmacological treatments. Cognitive behavior therapy (CBT) is currently the most well-studied and popular treatment modality [69]. In view of the fact that maternal stress and hair cortisol levels are associated with motor and cognitive neurodevelopment of the fetus at 6 months of age [70]. A recent randomized controlled trial showed that CBT reduced cortisol levels in the hair of pregnant women and improved psychological stress and psychiatric symptoms [71]. The decreased cortisol levels in the hair are beneficial to the physical and mental health of pregnant women and their fetuses, so the use of CBT for stress and negative emotions could be greatly encouraged.

CONCLUSION

COVID-19 affects fetal neurological development through multiple pathways during the pregnancy, although most newborns born in a COVID-19 pandemic setting are not directly infected with SARS-CoV-2. We need to pay attention not only to the neurological symptoms of neonatal impairment at birth, but also to the neuropsychiatric symptoms during the growth, and therefore improving the prognosis by early intervention. There is still a need for extensive follow-up studies to determine whether the fetal damage will be continued in adulthood, and new-onset psychiatric symptoms will be developed in adulthood. Most importantly, it is essential to create a safer environment and provide great support for pregnant women and their offspring.

REFERENCES

1. Rahman S, Montero MTV, Rowe K, Kirton R, Kunik F Jr. Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. Expert Rev Clin Pharmacol. 2021;14:601–21.
2. Chakraborty J, Mainy P. COVID-19 outbreak: Migration, effects on society, global environment and prevention. Sci Total Environ. 2020;728:138882.
3. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–207.
4. Dong L, Tian J, He S, Zhu C, Wang J, Liu C, et al. Possible vertical transmission of SARS-CoV-2 From an infected mother to her newborn. JAMA. 2020;323:1846–8.
5. Hosseini MS, Hosseini A, Ghaffari E, Radfar M, Shirvani F, Tabatabai S, et al. Evaluation of clinical outcomes of neonates born to mothers with coronavirus (COVID-19) in Shahid Beheshti Hospitals. J Educ Health Promot. 2021;10:173.
6. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurolgic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurology. 2020;77:683–90.
7. Puelles V, Lügteheftmann M, Lindemeyer MT, Sperhake JP, Wong MN, Allweiss L, et al. Multigene and Renal Tropism of SARS-CoV-2. N Engl J Med. 2020;383:590–2.
8. Solomon IH, Normandin E, Bhattacharyya S, Mekerji SS, Keller K, Ali AS, et al. Neuropsychopathological Features of Covid-19. N Engl J Med. 2020;383:989–92.
9. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of novel coronavirus in the United States. N Engl J Med. 2020;382:929–36.
10. Stiles J, Jernigan TL. The basics of brain development. Neurosci Res. 2010;20:327–48.
11. Kang HJ, Kawasawa YI, Cheng F, Zhu Y, Xu X, Li M, et al. Spatio-temporal transcriptome of the human brain. Nature. 2011;478:483–9.
12. Makvandi S, Mahdavian M, Kazemi-Nia G, Vahedian-Azimi A, Guest PC, Karimi L, et al. The 2019 novel coronavirus disease in pregnancy: a systematic review. Adv Exp Med Biol. 2021;1321:299–307.
13. Tanacak A, Yazihan N, Erol SA, Anuk AT, Yucel Yetiskin FD, Biriken D, et al. The impact of COVID-19 infection on the cytokine profile of pregnant women: A prospective case-control study. Cytokine. 2021;140:155431.
14. Robertson SA, Moldenhauer LM. Immunological determinants of implantation success. Int J Dev Biol. 2014;58:205–17.
15. Chow SS, Craig ME, Jones CA, Hall B, Catteau J, Lloyd AR, et al. Differences in amniotic fluid and maternal serum cytokine levels in early midtrimester women without evidence of infection. Cytokine. 2008;44:78–84.
16. Aizieh F, Dingle K, Raghupathy R, Johnson K, VanderPlas J, Ansari A. Multivariate analysis of cytokine profiles in pregnancy complications. Am J Reprod Immunol. 2018;79:e12818.
17. Zhou JZ, Way SS, Chen K. Immunology of the uterine and vaginal mucosa. Trends Immunol. 2018;39:302–14.
18. Lagunas-Rangel FA, Chávez-Valencia V. High IL-6/IFN-γ ratio could be associated with severe disease in COVID-19 patients. J Med Virol. 2020;92:1789–90.
19. Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest. 2020;130:2202–5.
20. Qiu X, Zhang L, Tong Y, Qu Y, Wang H, Mu D. Interleukin-6 for early diagnosis of neonatal sepsis with premature rupture of the membranes: a meta-analysis. Med (Baltim). 2018;97:e13146.
21. Chatterjee P, Chiasson VL, Bounds KR, Mitchell BM. Regulation of the Anti-Inflammatory Cytokines Interleukin-4 and Interleukin-10 during pregnancy. Front Immunol. 2014;5:253.
22. Juan J, Gil MM, Rong Z, Yang H, Poon LC. Effect of coronavirus disease 2019 (COVID-19) on maternal, perinatal and neonatal outcome: systematic review. Ultrasound Obstet Gynecol. 2020;56:15–27.
23. Ophelders D, Gussenhoven R, Klein L, Jellemra RK, Westerlaken RJ, Hütten MC, et al. Preterm brain injury, antenatal triggers, and therapies: timing is key. Cells. 2020;9:1871.
24. Leviton A, Allred EN, Fichorova RN, Kuban KC, Michael O’Shea T, Dammann O. Systemic inflammation on postnatal days 21 and 28 and indicators of brain dysfunction 2 years later among children born before the 28th week of gestation. Early Hum Dev. 2016;93:25–32.
25. Hoffman MC, Freedman R, Law AJ, Clark AM, Hunter SK. Maternal nutrients and effects of gestational COVID-19 infection on fetal brain development. Clin Nutr ESPEN. 2021;43:1–8.
26. Patterson PH. Neuroscience. Maternal effects on schizophrenia risk. Science. 2007;318:576–7.
27. Wang Y, Chen L, Wu T, Shi H, Li Q, Jiang H, et al. Impact of Covid-19 in pregnancy on mother’s psychological status and infant’s neurobehavioral development: a longitudinal cohort study in China. BMC Med. 2020;18:347.
28. Hashimoto Y, Suzuki T, Hashimoto K. Mechanisms of action of uvoxamine for depression: a translational study. Exp Med Biol. 2021;1321:299–307.
29. Smith SE, Li J, Garbett K, Mirmics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci. 2007;27:10695–702.
30. Brown AS, Hooton J, Schaefer CA, Zhang H, Petkova E, Babulas V, et al. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry. 2004;161:889–95.
31. Ganguli S, Chavali PL. Intrauterine viral infections: impact of inflammation on fetal neurodevelopment. Front Neurosci. 2021;15:717557.
32. Scola G, Duong A. Prenatal maternal immune activation and brain development with relevance to psychiatric disorders. Neuroscience. 2017;346:403–8.
33. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395:809–15.
34. Fisher KS, Cuscut FX, Rivera VM, Hutton GJ. Current advances in pediatric onset multiple sclerosis. Biomedicines. 2020;8:71.
35. CassoSanchez MF, Devalle S, Avan C, Capella D, Roque NR, Coelho-Aguiar JM, et al. Neuremehanisms of SARS-CoV-2: a review. Front Neuroanat. 2020;14:37.
36. Zengeler KE, Lukens JR. Innate immunity at the crossroads of healthy brain maturation and neurodevelopmental disorders. Nat Rev Immunol. 2021;21:454–68.
37. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020;87:18–22.
38. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.
39. Chen C, Zhang XR, Ju ZY, He WF. [Advances in the research of mechanism and related immunotherapy on the cytokine storm induced by coronavirus disease 2019]. Zhonghua Shao Shang Za Zhi. 2020;56:471–5.
40. Mahalakshmi AM, Ray B, Tuladhar S, Paneyala S, Patteswari D, et al. Does COVID-19 contribute to development of neurological disease? Immun Inflamm Di. 2021;9:48–58.
41. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7:11.
42. Wang Y, Di Y, Ye J, Wei W. Study on the public psychological states and its related factors during the outbreak of coronavirus disease 2019 (COVID-19) in some regions of China. Psychol Health Med. 2021;26:13–22.
43. Ren X, Huang W, Pan H, Huang T, Wang X, Ma Y. Mental health during the Covid-19 outbreak in China: a meta-analysis. Psychiatry Q. 2020;91:1033–45.
44. Basu A, Kim HH, Basaldua R, Chou KW, Charrom L, Kessali N, et al. A cross-national study of factors associated with women's perinatal mental health and wellbeing during the COVID-19 pandemic. PLoS ONE. 2021;16:e0249780.
45. Lahti M, Savolainen K, Tuovinen S, Pesonen AK, Lahti J, Heinonen K, et al. Maternal depressive symptoms during and after pregnancy and psychiatric problems in children. J Am Acad Child Adolesc Psychiatry. 2017;56:30–39.e37.
46. Suzuki A, Irima M, Hayashi S, Sato Y, Azuma K, Kubo KY. Maternal chewing during prenatal stress ameliorates stress-induced hypomyelination, synaptic alterations, and learning impairment in mouse offspring. Brain Res. 2016;1651:136–43.
47. Thomason MS, Hect JL, Waller R, Curtin P. Interactional relations between maternal prenatal stress, fetal brain connectivity, and gestational age at delivery. Neuropsychopharmacology. 2021;46:1839–47.
48. Deoni SC, Beauchemin J, Viole A, V DS. Impact of the COVID-19 pandemic on early child cognitive development: initial findings in a longitudinal observational study of child health. medRxiv 2021.
49. Wenner Moyer M. The COVID generation: how is the pandemic affecting kids' brains? Nature. 2022;601:180–3.
50. Glover V, O'Donnell KL, Connor TG, Fisher J. Prenatal maternal stress, fetal programming, and mechanisms underlying later psychopathology: A global perspective. Dev Psychopathol. 2018;30:483–54.
51. Pulli EP, Kumpulainen V, Kasurinen JH, Karlsson R, et al. Prenatal exposure and infant brain: review of magnetic resonance imaging studies and a population description analysis. Hum Brain Mapp. 2019;20:1619–202.
52. Freeman R, Hunter SK, Law AJ, D'Alessandro A, Noonan K, Wyrwa A, et al. Maternal choline and respiratory coronavirus effects on fetal brain development. J Psychiatr Res. 2020;128:1–4.
53. Zhang Q, Chen H, Wang Y, Zhang C, Tang Z, Li H, et al. Severe vitamin D deficiency in the first trimester is associated with placental inflammation in high-risk singleton pregnancy. Clin Nutr. 2019;38:1921–6.
54. Bobbitt KR, Peters RM, Li J, Rao SD, Woodcroft KJ, Cassidy-Bushrow AE. Early pregnancy vitamin D and patterns of antenatal inflammation in African-American women. J Reprod Immunol. 2015;107:52–58.
55. Fasahai Y. Drug repurposing of selective serotonin reuptake inhibitors: could these drugs help fight COVID-19 and save lives? J Clin Neurosci. 2021;88:163–72.
56. Mezzacappa A, Lasica PA, Gianfagna F, Cazas O, Hardy P, Falissard B, et al. Risk for autism spectrum disorders according to period of prenatal antidepressant exposure: a systematic review and meta-analysis. JAMA Pediatr. 2017;11:555–563.
57. Dragioti E, Solmi M, Favaro A, Fusiari-Poli P, Dazian P, Thompson T, et al. Association of antidepressant use with adverse health outcomes: a systematic umbrella review. JAMA Psychiatry. 2019;76:1241–55.
58. Zhang A, Bornheimer LA, Weaver A, Franklin C, Hai AH, Guz S, et al. Cognitive behavioral therapy for primary care depression and anxiety: a secondary meta-analytic review using robust variance estimation in meta-regression. J Behav Ther Res. 2019;42:1117–41.
59. Caparros-Gonzalez RA, Romero-Gonzalez B, Gonzalez-Perez R, Lucena-Prieto L, Perez-Garcia M, Cruz-Quintana F, et al. Maternal and neonatal hair cortisol levels are associated with infant neurodevelopment at six months of age. J Clin Med. 2019;8:2015.
60. Romero-Gonzalez B, Puertas-Gonzalez JA, Strivens-Vilchez H, Gonzalez-Perez R, Peralta-Ramirez M. Effects of cognitive-behavioural therapy for stress management on stress and hair cortisol levels in pregnant women: a randomised controlled trial. J Psychosom Res. 2020;135:10162.

ACKNOWLEDGEMENTS
This study was supported by grants from the National Natural Science Foundation of China (81974171, 81703482, 82070405, and 82101270), Innovative and Entrepreneurial Team of Jiangsu Province (JSSCTD202144), and the Natural Science Foundation of Jiangsu Province (BK20210975).

AUTHOR CONTRIBUTIONS
CY and LY conceived the scientific ideas; RW and ZW wrote the draft manuscript; CH, KH, CY, and LY revised the manuscript; All the authors approved the submission.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to Ling Yang or Chun Yang.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
